Good morning, folks. And how are you today? We are in fine spirits, thanks to a sunny sky and a delightful breeze that are enveloping the Pharmalot campus. Of course, there is little time to enjoy the moment since there is so much to be done. It is the middle of the week, after all. No doubt, you can relate. So time to get cracking. Let’s grab that cup of stimulation and attack the to-do list. Meanwhile, here are some items of interest. Hope you conquer the world today and keep us in mind if you hear anything interesting. …
A monoclonal antibody treatment for Covid-19 developed by Regeneron Pharmaceuticals (REGN) saved lives among hospitalized patients who had not mounted their own immune response, a finding that could dramatically change the way that doctors will use the therapy, STAT explains. The new data from a trial of nearly 10,000 patients mark the first time that a medicine that works by fighting the SARS-CoV-2 virus has been shown to reduce mortality.
Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group is urging the Biden administration to request resignations from or remove three top Food and Drug Administration officials, including acting agency commissioner Janet Woodcock, STAT says. The approval “showed a stunning disregard for science, eviscerated the agency’s standards for approving new drugs, and ranks as one of the most irresponsible and egregious decisions in the history of the agency,” Public Citizen wrote to Health and Human Services Secretary Xavier Becerra.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect